<DOC>
	<DOCNO>NCT02966964</DOCNO>
	<brief_summary>The patient meet inclusion/exclusion criterion assign Test1 group Test 2 group control group randomly . All subject take one pill Viread® Tab . ( Tenofovir Disoproxil Fumarate 300mg ) day 48 week . At time , randomized subject take two pill Ursa® Tab . Placebo Ursa® Tab . twice day 48 week .</brief_summary>
	<brief_title>A Clinical Trials Evaluate Efficacy Safety Tenofovir With Without UDCA Patients With HBV</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Patients age 19 69 year time agreement 2 . Patients HBsAgpositive least within 24 week diagnosis chronic hepatic disease image test within 24 week time screen . 3 . Patients HBeAgpositive HBV DNA level≥20,000 IU/mL , HBeAgnegative HBV DNA level≥2,000 IU/mL 4 . Patients never treat Tenofovir 5 . Patients whose ALT level 2 time UNL time screen 6 . Patients prothrombin time prolonged≤4sec time screen 7 . Patients Total bilirubin level≤3.0mg/dL time screen 8 . Patients albumin level≥3.0g/dL time screen 9 . Patients ELF score≥8.5 time screen 10 . Patients agree clinical trial voluntarily sign agreement 1 . HIV , HCV HDV infedted patient 2 . Patients abnormal liver function cause disease ( e.g . hematochromatosis , Wilson 's disease , alcoholic hepatitis , Nonalcoholic steatohepatitis , alpha 1 antitrypsin deficiency ) 3 . Patients suffer variceal haemorrhage hepatic encephalopathy 4 . Patients need/had liver transplant 5 . Patients severe biliary obstruction , fulminant hepatic failure , radioopacity gallstone , nonfunctional gall bladder , acute cholecystitis , Lactic acidosis/ adiposis 6 . Patients enteritis colitis like peptic ulcer Crohn 's disease 7 . Patients significant kidney disease , cardiovascular disease , lung disease , nervous disease , selfimmune disease , bone disease ( ex : osteomalacia , osteopenia , chronic osteomyelitis , osteopsathyrosis , osteochondrosis , multiple fracture ) malignant tumor . 8 . Patients systemic infection 9 . Patients hypersensitivity ursodeoxycholic acid Tenofovir 10 . Patients generic problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption 11 . Patients describe time screen Hb &lt; 8g/dL eGFR &lt; 60mL/min/1.73m2 AFP level &gt; 200ng/mL diagnosis hepatocellular carcinoma base radiology result within 24 week 12 . Patients immune cytokinebased antiviral agent treatment ( ex . Interferon α , Peginterferon α ) , immunosuppression therapy ( ex . Cyclosporine , Tacrolimus ) 24 week time screen 13 . Patients use contraindication comedication drug clinical trial ca n't get washout period 14 . Women childbearing potential use effective birth control method 15 . Patients psychiatric disorder drug alcohol abuse , ca n't understand purpose process clinical trial 16 . Patients participate clinical trial 30 day prior enrollment study 17 . Patients determine inappropriate investigator participate study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>